mounjaro glp 1 gip Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort Mounjaro (tirzepatide) for the Treatment
Description
If a provider clears you to start, you begin at a low dose, and the dose steps up slowly over several weeks
Regular monitoring may be advised for some patients, especially during the initial months of GLP-1 treatment when side effects are most common
Reinitiation Criteria: Clinicians should consider increasing the dose or reinitiating therapy if a patient experiences more than 5% weight regain
Sometimes the hair cycle blinks
In just a few months, Ive already seen my investment returned and more
